Journals / Klimik Dergisi / 2016 / Cilt: 29 - Sayı: 3

Hepatocellular Carcinoma in a Chronic Hepatitis B Patient With Suppressed Viral Replication

Viral Baskılanma Sağlanan Kronik Hepatit B Hastasında Hepatoselüler Kanser Gelişimi

Pages
130–132
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although viral suppression is achieved in patients with chronic hepatitis B, followup and HCC screening should be done regularly in patients who have HCC risk factors such as thrombocytopenia and older age, as in this case.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Suppressing viral replication is the main intervention for prevention of hepatocellular carcinoma (HCC) development, which is one of the purposes of treatment of chronic hepatitis B.
📊
Key Findings & Data:We report a case of HCC in a 73-year-old woman with chronic hepatitis B who was treated and whose viral replication was successfully suppressed with antiviral therapy.
💡
Conclusion & Impact:Although viral suppression is achieved in patients with chronic hepatitis B, followup and HCC screening should be done regularly in patients who have HCC risk factors such as thrombocytopenia and older age, as in this case.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Suppressing viral replication is the main intervention for prevention of hepatocellular carcinoma (HCC) development, which is one of the purposes of treatment of chronic hepatitis B. We report a case of HCC in a 73-year-old woman with chronic hepatitis B who was treated and whose viral replication was successfully suppressed with antiviral therapy. The patient had anti-HBe positivity and her viral load was 1.01x106 IU/mL. Telbivudine treatment led to a decrease of HBV DNA below the detection limit on the second month of the treatment. But her ?-fetoprotein level increased (121 ng/L) on the 30th month of the treatment. Magnetic resonance imaging showed a mass compatible with HCC on the liver and a biopsy revealed HCC. She was treated with chemo-embolization. Although viral suppression is achieved in patients with chronic hepatitis B, followup and HCC screening should be done regularly in patients who have HCC risk factors such as thrombocytopenia and older age, as in this case.

Özet

Kronik hepatit B tedavisinin amaçlarından biri olan hepatoselüler kanser (HSK) gelişiminin önlenmesinde, viral replikasyonun baskılanması müdahale edilebilir başlıca faktördür. Bu bildiride, antiviral tedaviyle viral baskılanma sağlanmasına rağmen HSK gelişen, 73 yaşındaki kadın olgu sunulmaktadır. Kronik hepatit B saptanan, anti-HBe-pozitif ve viral yükü 1.01x106 İÜ/ml olan hastaya telbivudin tedavisi başlandı. Hızlı virolojik yanıt alınan ve viral baskılaması devam etmekte olan hastada, tedavinin 30'uncu ayında ?-fetoprotein değeri 121 ng/lt olarak saptandı. Yapılan üst karın manyetik rezonans görüntülemesinde karaciğerde HSK ile uyumlu kitle saptandı ve biyopsiyle tanı doğrulandı. Hasta kemo-embolizasyon yöntemiyle tedavi edildi. Viral baskılanma sağlanmış olsa da kronik hepatit B hastalarında, bu olguda olduğu gibi ileri yaş, trombositopeni ve diğer HSK risk faktörlerinin varlığında, kontrol ve HSK taramalarının düzenli olarak yapılması yararlı olacaktır.

🔖

Cite This Article

DÜNYA, A. E., AĞLADIOĞLU, K., SAYIN, S. K., KUTLU, M. (2022). Hepatocellular Carcinoma in a Chronic Hepatitis B Patient With Suppressed Viral Replication. Klimik Dergisi, Cilt: 29 - Sayı: 3, 130–132. https://ajindex.com/articles/573597

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Akhan S, Aynıoğlu A, Çağatay A, et al. Kronik Hepatit B Virusu İnfeksiyonunun Yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Raporu. Klimik Derg. 2014
  2. 27(Suppl. 1): 2-18. [CrossRef] Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellu- lar carcinoma. Aliment Pharmacol Ther. 2008
  3. 28(9): 1067-77. [CrossRef] Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in pati- ents with chronic hepatitis B: a nationwide cohort study. Gastro- enterology. 2014
  4. 147(1):143-51. [CrossRef] Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol. 2015
  5. 7(8): 1064-73. [CrossRef] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006
  6. 295(1): 65-73. [CrossRef] Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B sur- face antigen increase risk of hepatocellular carcinoma in pati- ents with low HBV load. Gastroenterology. 2012
  7. 142(5): 1140-9. [CrossRef] Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B virus precore/ core promoter mutations and serum viral load on noncirrho- tic hepatocellular carcinoma: a case-control study. J Infect Dis. 2006
  8. 194(5): 594-9. [CrossRef] Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010
  9. 53(2): 348-56. [CrossRef] Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chro- nic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015
  10. 64(8): 1289-95. [CrossRef] Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Vi- rological suppression does not prevent the development of he- patocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011
  11. 60(8): 1109-16. [CrossRef] Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofo